olaparib

April 22, 2019

Lynparza Plus Investigational Alpelisib Is Promising for Epithelial Ovarian Cancer

News

A combination of Lynparza (olaparib) and the investigational PI3K inhibitor alpelisib is safe for the treatment of recurrent epithelial ovarian cancer and induces at least stable disease in more than ... Read more

February 13, 2019

Lynparza Plus Weekly Chemotherapy May Help Patients with Advanced Disease, Phase 1/2 Study Finds

News

A combination of oral Lynparza (olaparib) and weekly chemotherapy can be safely given to heavily treated ovarian cancer patients and shows signs of efficacy, particularly among those with BRCA mutations, a ... Read more

January 18, 2019

Lynparza Improves Response Rate in Relapsed BRCA-mutated Advanced OC Patients

News

Results of a Phase 3 clinical trial show that Lynparza (olaparib) tablets met the primary goal of significantly improving the objective response rate, which is the percentage of patients whose cancer shrinks or ... Read more

January 4, 2019

Lynparza Approved in U.S. as First-line Maintenance Therapy for BRCA-positive Advanced Ovarian Cancer

News

Women with BRCA-mutated advanced ovarian cancer living in the United States can now receive Lynparza (olaparib), developed by AstraZeneca and Merck, as a maintenance treatment for their partial or complete response to first-line ... Read more

November 26, 2018

UK’s NICE Recommends Against Lynparza Tablets on NHS for Advanced, Platinum-sensitive Ovarian Cancers

News

The U.K.’s National Institute of Health and Care Excellence (NICE) has decided not to recommend Lynparza (olaparib) tablets as maintenance treatment for women with relapsed ovarian cancer who respond to platinum-based chemotherapy ... Read more

November 16, 2018

FDA Gives Priority Review to Lynparza as First-line Maintenance Therapy for Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has agreed to review the use of Lynparza (olaparib) tablets as a maintenance treatment for women newly diagnosed with advanced ovarian cancer, Merck announced ... Read more

July 27, 2018

Lynparza Maintenance for Ovarian Cancer Takes No Toll on Quality of Life, Study Shows

News

Ovarian cancer patients who responded to platinum-based chemotherapy after failing at least one prior treatment may take Lynparza (olaparib) as maintenance therapy without worrying about their quality of life, a new study ... Read more

July 16, 2018

Lynparza Maintenance Delays Disease Progression in Advanced Ovarian Cancer, Phase 3 Trial Shows

News

Lynparza (olaparib), a PARP inhibitor, significantly prevents ovarian cancer from progressing or returning in women who responded to their first-line chemotherapy treatment, results from a Phase 3 trial show. The randomized, ... Read more

February 26, 2018February 26, 2018

EMA’s CHMP Recommends Lynparza as Maintenance Therapy for Platinum-sensitive Ovarian Cancer

News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that Lynparza (olaparib) be approved to prevent disease progression and relapse in ovarian cancer patients who responded to platinum-based ... Read more

January 29, 2018

Tablet Form of Lynparza Approved in Japan as Maintenance Therapy for Recurrent Ovarian Cancer

News

Japanese women with advanced ovarian cancer can now be treated with the new tablet formulation of Lynparza (olaparib) after a recent approval by the Japanese Ministry of Health, Labour and ... Read more